

Title	Influence of manipulating hypoxia in solid tumors on the radiation dose-rate effect in vivo, with reference to that in the quiescent cell population.
Author(s)	Masunaga, Shin-ichiro; Hirayama, Ryoichi; Uzawa, Akiko; Kashino, Genro; Takata, Takushi; Tanaka, Hiroki; Suzuki, Minoru; Kinashi, Yuko; Liu, Yong; Koike, Sachiko; Ando, Koichi; Ono, Koji
Citation	Japanese journal of radiology (2010), 28(2): 132-142
Issue Date	2010-02
URL	<a href="http://hdl.handle.net/2433/128868">http://hdl.handle.net/2433/128868</a>
Right	The original publication is available at <a href="http://www.springerlink.com">www.springerlink.com</a>
Type	Journal Article
Textversion	author

Editorial Manager(tm) for Japanese Journal of Radiology  
Manuscript Draft

Manuscript Number: RMED-273R3

Title: Influence of manipulating hypoxia in solid tumors on radiation dose-rate effect in vivo, referring to that in quiescent cell population

Article Type: Original Article

Keywords: Dose-rate effect; Manipulating hypoxia; Quiescent cell; Carbon-ion beams; Gamma-rays

Corresponding Author: Dr. Shin-ichiro Masunaga, M.D., Ph.D.

Corresponding Author's Institution: Research Reactor Institute, Kyoto University

First Author: Shin-ichiro Masunaga, M.D., Ph.D.

Order of Authors: Shin-ichiro Masunaga, M.D., Ph.D.; Ryoichi Hirayama, Ph.D.; Akiko Uzawa, Ph.D.; Genro Kashino, Ph.D.; Takushi Takata, Ph.D.; Hiroki Tanaka, Ph.D.; Minoru Suzuki, M.D., Ph.D.; Yuko Kinashi, M.D., Ph.D.; Yong Liu, M.D., Ph.D.; Sachiko Koike, Ph.D.; Koichi Ando, Ph.D.; Koji Ono, M.D., Ph.D.

**Influence of manipulating hypoxia in solid tumors on radiation dose-rate effect *in vivo*, referring to that in quiescent cell population**

Shin-ichiro Masunaga<sup>1</sup>, Ryoichi Hirayama<sup>2</sup>, Akiko Uzawa<sup>2</sup>, Genro Kashino<sup>1</sup>, Takushi Takata<sup>3</sup>, Hiroki Tanaka<sup>4</sup>, Minoru Suzuki<sup>1</sup>, Yuko Kinashi<sup>5</sup>, Yong Liu<sup>1</sup>, Sachiko Koike<sup>2</sup>, Koichi Ando<sup>6</sup> and Koji Ono<sup>1</sup>

<sup>1</sup> *Particle Radiation Oncology Research Center, <sup>4</sup> Radiation Medical Physics and <sup>5</sup> Radiation Safety and Control, Research Reactor Institute, Kyoto University, Kumatori, Osaka, Japan.*

<sup>2</sup> *Heavy-Ion Radiobiology Research Group, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.*

<sup>3</sup> *Wakasawan Energy Research Center, Tsuruga, Fukui, Japan.*

<sup>6</sup> *Heavy Ion Medical Center, Gunma University, Gunma, Japan.*

**Running head:**

Influence of manipulating hypoxia on radiation dose-rate effect

**All correspondence to:**

Shin-ichiro Masunaga, M.D., Ph.D.

Particle Radiation Oncology Research Center  
Research Reactor Institute, Kyoto University  
2-1010, Asashiro-nishi, Kumatori-cho,  
Sennan-gun, Osaka 590-0494, Japan.

Tel: +81-72-451-2406, 2487, Fax: +81-72-451-2627

E-mail: smasuna@rri.kyoto-u.ac.jp

**Acknowledgments**

This study was supported, in part, by a Grant-in-aid for Scientific Research (C) (20591493) from the Japan Society for the Promotion of Science.

**Original article**

**The authors declare no conflicts of interest concerning this study.**

1 **Abstract**

2 **Purpose:** To clarify the effect of manipulating intratumor hypoxia on  
3 **radiosensitivity** under reduced dose-rate (RDR) irradiation.

4  
5  
6 **Methods:** Tumor-bearing mice were continuously given  
7  
8 5-bromo-2'-deoxyuridine (BrdU) to label all proliferating (P) cells.  
9  
10 They received  $\gamma$ -rays or accelerated carbon-ion beams at high dose-rate  
11  
12 (HDR) or RDR with or without tumor clamping to induce hypoxia. Some  
13  
14 mice without clamping received nicotinamide, an acute hypoxia-releasing  
15  
16 agent or misonidazole, a hypoxic cell radio-sensitizer before  
17  
18 irradiation. The responses of quiescent (Q) and total (= P+Q) cells  
19  
20 were assessed by the micronucleus frequency using immunofluorescence  
21  
22 staining for BrdU.  
23  
24

25 **Results:** The clearer decrease in **radiosensitivity** in Q than total cells  
26  
27 after RDR  $\gamma$ -ray irradiation was suppressed with carbon-ion beams,  
28  
29 especially with a higher linear energy transfer value. Repressing the  
30  
31 decrease in the **radiosensitivity** under RDR irradiation through keeping  
32  
33 tumors hypoxic during irradiation and enhancing the decrease in the  
34  
35 **radiosensitivity** by nicotinamide were clearer with  $\gamma$ -rays and in total  
36  
37 cells than with carbon-ion beams and in Q cells, respectively. Inhibiting  
38  
39 the decrease in the **radiosensitivity** by misonidazole was clearer with  
40  
41  $\gamma$ -rays and in Q cells than with carbon-ion beams and in total cells,  
42  
43 respectively.  
44  
45

46 **Conclusion:** Manipulating hypoxia during RDR as well as HDR irradiation  
47  
48 influences tumor **radiosensitivity**, especially with  $\gamma$ -rays.  
49  
50

51  
52  
53 **Key words:**

54  
55 Dose-rate effect; Manipulating hypoxia; Quiescent cell; Carbon-ion  
56  
57 beams;  $\gamma$ -Rays  
58  
59  
60  
61  
62  
63  
64  
65

## 1 Introduction

2 Intensity modulated radiotherapy (IMRT) and stereotactic  
3 irradiation have become common as a new radiotherapy technique for  
4 treatment of malignancies. Both modalities generally use multiple arc  
5 or fixed-portal radiation beams, and radiation beams are exposed  
6 intermittently. These techniques often require 30 min or a longer time  
7 in one treatment session for precise positioning of patients.<sup>1,2</sup>  
8 Prolongation of irradiation time may reduce a radiation effect, and  
9 evokes a major concern for the dose rate effect. Thus, it is needed  
10 to clarify the effect of the reduction of dose rate on the  
11 radiosensitivity of tumors *in vivo*.

12 When using low linear energy transfer (LET) radiation, lowering  
13 the dose rate is thought to reduce late effects in normal tissue much  
14 more than it decreases tumor control. Thus, the "therapeutic ratio"  
15 increases as the dose rate decreases, because the therapeutic ratio  
16 is equal to the ratio of tumor control to normal tissue complications.  
17 Further, the difference between early and late effects for low dose-rate  
18 radiotherapy, as well as improving the therapeutic ratio, allows  
19 complete treatment in a short period of time, minimizing the effects  
20 of tumor repopulation. In other words, decreasing the dose rate  
21 increases the therapeutic ratio, limited only by tumor cell  
22 repopulation.<sup>3</sup> This is the primary rationale for low dose-rate  
23 radiotherapy using low LET radiation. High LET radiation is more  
24 effective than low LET X- or  $\gamma$ -radiation at inducing biologic damage.  
25 High LET radiation results in a greater relative biological  
26 effectiveness (RBE) value for cell killing, a reduced oxygen effect,  
27 and a reduced dependence on the cell cycle and the irradiation dose

1 rate.<sup>4</sup>

2  
3 Manipulating hypoxia in solid tumors during irradiation apparently  
4 influences tumor radiosensitivity under high dose-rate (HDR)  
5 irradiation using low LET radiation.<sup>5</sup> However, its significance in solid  
6 tumors irradiated at a reduced dose rate (RDR) is less clear *in vivo*,  
7 whether low or high LET radiation is employed.  
8  
9

10 Many cells in solid tumors are quiescent *in situ* but still  
11 clonogenic.<sup>6</sup> The quiescent (Q) tumor cells are more resistant to low-LET  
12 radiation because of their larger hypoxic fraction and greater capacity  
13 to recover from potentially lethal damage (PLD) than proliferating (P)  
14 tumor cells. The rationale for low dose-rate radiotherapy does not take  
15 into account the response of Q tumor cells at all.  
16  
17

18 Thus, in this study, we tried to elucidate the effect of  
19 manipulating hypoxia in irradiated solid tumors at a RDR with low-LET  
20  $\gamma$ -rays or high-LET 290 MeV/u accelerated carbon-ion beams *in vivo*,  
21 compared with HDR irradiation. Further, the responses of the total (=   
22 P + Q) and Q cell populations in irradiated solid tumors were separately  
23 detected with the method for selectively detecting the response of Q  
24 cells within solid tumors.<sup>7</sup> This is the first attempt to clarify the  
25 direct relationship between the irradiation dose rate effect and the  
26 oxygen effect *in vivo*, referring to the response of the Q cell population  
27 in irradiated solid tumors.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Materials and Methods

### Mice and tumors

SCC VII squamous cell carcinoma cell line derived from C3H/He mice was maintained *in vitro* in Eagle's minimum essential medium supplemented with 12.5 % fetal bovine serum. The tumor cells ( $1.0 \times 10^5$ ) were inoculated subcutaneously into the left hind leg of 9-week-old syngeneic female C3H/He mice (Japan Animal Co., Ltd., Osaka, Japan). Fourteen days later, the tumors, approximately 1 cm in diameter, were employed for experimental treatment, and the body weight of the tumor-bearing mice was  $22.1 \pm 2.3$  (Mean  $\pm$  SD) g. Mice were handled according to the Recommendations for Handling of Laboratory Animals for Biomedical Research, compiled by the Committee on Safety Handling Regulations for Laboratory Animal Experiments. Incidentally, the p53 of SCC VII tumor cells is the wild type.<sup>7</sup>

### Labeling with 5-bromo-2'-deoxyuridine (BrdU)

Nine days after the inoculation, mini-osmotic pumps (Durect Corporation, Cupertino, CA) containing BrdU dissolved in physiological saline (250 mg/ml) were implanted subcutaneously to label all P cells for 5 days. The percentage of labeled cells after continuous labeling with BrdU was  $55.3 \pm 4.5$  %, and reached a plateau at this stage. Therefore, tumor cells not incorporating BrdU after continuous labeling were regarded as Q cells.

### Treatment

After the labeling with BrdU, tumor-bearing mice received  $\gamma$ -ray or accelerated carbon-ion whole-body irradiation, with the animal held in a specially designed device made of acrylic resin with the tail or all four legs firmly fixed with adhesive tape with no anesthetic. Some tumors were made totally hypoxic by clamping the proximal end 15 min

1 before irradiation.<sup>7</sup> This clamping for 15 min did not influence  
2  
3 clonogenic cell survival or the level of micronucleation.

4  
5  $\gamma$ -Rays were delivered with a cobalt-60  $\gamma$ -ray irradiator at a dose  
6  
7 rate of 2.5 or 0.039 Gy/min.

8  
9 Carbon-12 ions were accelerated up to 290 MeV/u by the synchrotron  
10  
11 of the Heavy Ion Medical Accelerator installed at National Institute  
12  
13 of Radiological Sciences in Chiba, Japan. The dose rate was regulated  
14  
15 through a beam attenuation system, and irradiation was conducted using  
16  
17 horizontal carbon beams with a dose rate of 1.0 or 0.035 Gy/min. The  
18  
19 LET of the carbon ion beam with the 6-cm spread-out Bragg peak (SOBP)  
20  
21 ranges from 14 keV/ $\mu$ m to greater than 200 keV/ $\mu$ m, depending on depth.  
22  
23 A desired LET beam was obtained by selecting the depth along the beam  
24  
25 path using a Lucite range shifter. An LET of 18 and 50 keV/ $\mu$ m at the  
26  
27 middle of the plateau and the SOBP were employed here, respectively.<sup>8</sup>  
28  
29  
30

31 Irradiated tumor-bearing mice were divided into 4 groups. I) Tumors  
32  
33 were excised immediately after irradiation only under aerated  
34  
35 conditions. II) Tumors were kept totally hypoxic during irradiation,  
36  
37 then excised immediately after irradiation. III) The tumor-bearing mice  
38  
39 received an intraperitoneal administration of an acute  
40  
41 hypoxia-releasing agent, nicotinamide (1000 mg/kg of mouse weight)  
42  
43 dissolved in physiological saline 60 min before irradiation, then the  
44  
45 tumors were excised immediately after irradiation under aerated  
46  
47 conditions. IV) The tumor-bearing mice received an intraperitoneal  
48  
49 administration of a hypoxic cell radio-sensitizer, misonidazole (1000  
50  
51 mg/kg of mouse weight) dissolved in physiological saline 30 min before  
52  
53 irradiation, then the tumors were excised immediately after irradiation  
54  
55 under aerated conditions. All the doses employed, sequences and timing  
56  
57 for nicotinamide, misonidazole and irradiation were appropriate enough  
58  
59  
60  
61  
62  
63  
64  
65



1 to function completely<sup>9,10</sup>.

2 Each treatment group also included mice not pretreated with BrdU.

3  
4 ***Immunofluorescence staining of BrdU-labeled cells and micronucleus (MN)***  
5  
6  
7 ***assay***  
8

9 Tumors excised from the mice given BrdU were minced and trypsinized  
10 [0.05% trypsin and 0.02% ethylenediamine-tetraacetic acid (EDTA) in  
11 phosphate-buffered saline (PBS), 37 °C, 20 min]. Tumor cell suspensions  
12 were incubated for 72 h in tissue culture dishes containing complete  
13 medium and 1.0 µg/ml of cytochalasin-B to inhibit cytokinesis while  
14 allowing nuclear division, and the cultures were then trypsinized and  
15 cell suspensions were fixed. After the centrifugation of fixed cell  
16 suspensions, the cell pellet was resuspended with cold Carnoy's fixative  
17 (ethanol:acetic acid = 3:1 in volume). The suspension was placed on  
18 a glass microscope slide and the sample was dried at room temperature.  
19 The slides were treated with 2 M hydrochloric acid for 60 min at room  
20 temperature to dissociate the histones and partially denature the DNA.  
21 The slides were immersed in borax-borate buffer (pH 8.5) to neutralize  
22 the acid. BrdU-labeled tumor cells were detected by indirect  
23 immunofluorescence staining using a monoclonal anti-BrdU antibody  
24 (Becton Dickinson, San Jose, CA) and a fluorescein isothiocyanate  
25 (FITC)-conjugated antimouse IgG antibody (Sigma, St. Louis, MO). To  
26 observe the double staining of tumor cells with green-emitting FITC  
27 and red-emitting propidium iodide (PI), cells on the slides were treated  
28 with PI (2 µg/ml in PBS) and monitored under a fluorescence microscope.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 The MN frequency in cells not labeled with BrdU could be examined  
54 by counting the micronuclei in the binuclear cells that showed only  
55 red fluorescence. The MN frequency was defined as the ratio of the number  
56 of micronuclei in the binuclear cells to the total number of binuclear  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 cells observed.<sup>7</sup> The MN frequency has already been shown to be a tool  
2  
3 for detecting radiosensitivity to carbon-ion beams.<sup>11</sup>  
4

5 The ratios obtained in tumors not pretreated with BrdU indicated  
6  
7 the MN frequency at all phases in the total tumor cell population. More  
8  
9 than 400 binuclear cells were counted to determine the MN frequency.  
10

### 11 **Clonogenic cell survival assay**

12  
13 The clonogenic cell survival assay was also performed in the mice  
14  
15 given no BrdU using an *in vivo-in vitro* assay method. Tumors were  
16  
17 disaggregated by stirring for 20 min at 37 °C in PBS containing 0.05 %  
18  
19 trypsin and 0.02% EDTA. The cell yield was  $(4.5 \pm 1.1) \times 10^7$ /g tumor  
20  
21 weight.  
22  
23

24  
25 As stated above, the MN frequencies for Q cells were obtained from  
26  
27 non-labeled tumor cells after continuous BrdU labeling. The MN  
28  
29 frequencies and surviving fractions for the total cell population were  
30  
31 obtained from cells in tumors not pretreated with BrdU. Thus, there was  
32  
33 no effect of interaction between BrdU and irradiation on the values of  
34  
35 MN frequency and SF. More than 3 tumor-bearing mice were used to assess  
36  
37 each set of conditions and each experiment was repeated at least twice.  
38  
39 To examine the differences between pairs of values, Student's *t*-test  
40  
41 was used when variances of the two groups could be assumed to be equal;  
42  
43 otherwise the Welch *t*-test was used.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Results

The plating efficiency and MN frequency at 0 Gy are shown in **Table 1**. The plating efficiency was significantly smaller for the combination with MISO than for any other condition in the total cell population. In both the total and Q cell populations, the MN frequency significantly increased in the following order: absolute control < totally hypoxic conditions < combination with nicotinamide < combination with misonidazole. Further, the MN frequency was significantly higher for Q cell population than the total cell population under all conditions.

Cell survival curves for the total tumor cells as a function of radiation dose after  $\gamma$ -ray irradiation are shown in **Figure 1**. For both HDR and RDR irradiation, the surviving fractions (SFs) decreased in the following order: irradiation under totally hypoxic conditions > aerobic irradiation without any drug > irradiation after nicotinamide loading > irradiation after misonidazole loading. The SFs under all conditions increased as the dose rate of radiation decreased, especially after nicotinamide loading.

Cell survival curves for the total tumor cells as a function of radiation dose after accelerated carbon-ion beam irradiation with an LET of 18 and 50 keV/ $\mu\text{m}$  are shown in the left and right panels of **Figure 2**, respectively. For both HDR and RDR irradiation, the SFs decreased in the same order as for  $\gamma$ -ray irradiation, but the degree of change was reduced, especially with 50 keV/ $\mu\text{m}$  carbon-ion beams. The increases in the SF with the decrease in dose rate were suppressed compared with  $\gamma$ -ray irradiation, again especially with 50 keV/ $\mu\text{m}$  carbon-ion beams.

For baseline correction, we used the normalized MN frequency to exclude the MN frequency in non-irradiated tumors. The normalized MN

1 frequency was the MN frequency in the irradiated tumors minus that in  
2 the non-irradiated tumors. Dose response curves of the normalized MN  
3 frequency for total and Q tumor cell populations as a function of  
4 radiation dose after  $\gamma$ -ray irradiation are shown in the left and right  
5 panels of **Figure 3**, respectively. Overall, the normalized MN frequencies  
6 were significantly smaller in Q cells than the total cells. In both total  
7 and Q cells, under RDR as well as HDR irradiation, the normalized MN  
8 frequencies increased in the following order: irradiation under totally  
9 hypoxic conditions < aerobic irradiation without drugs < irradiation  
10 after nicotinamide loading < irradiation after misonidazole loading.  
11 The normalized MN frequencies decreased with the decrease in dose rate  
12 under all conditions, especially irradiation after nicotinamide loading  
13 in the total cell population.

14 Dose response curves of the normalized MN frequency for the total  
15 and Q tumor cells as a function of radiation dose after accelerated  
16 carbon-ion beam irradiation with an LET of 18 (**Figure 4**) or 50 keV/ $\mu$ m  
17 (**Figure 5**) are shown in the left and right panels, respectively. Overall,  
18 the normalized MN frequencies were significantly smaller in Q cells than  
19 total cells, but the differences in **radiosensitivity** between the total  
20 and Q cells were reduced compared with  $\gamma$ -ray irradiation, especially  
21 with 50 keV/ $\mu$ m carbon-ion beams. In both the total and Q cells, under  
22 RDR as well as HDR irradiation, the normalized MN frequencies increased  
23 in the same order as for  $\gamma$ -ray irradiation, but the degree of change  
24 was reduced, especially with 50 keV/ $\mu$ m carbon-ion beams. The decreases  
25 in the normalized MN frequency with the decrease in radiation dose rate  
26 were suppressed compared with  $\gamma$ -ray irradiation, again especially with  
27 50 keV/ $\mu$ m carbon-ion beams.

1 To estimate the effect of aerobic irradiation compared with hypoxic  
2 irradiation in both the total and Q cells, the data for aerobic  
3 irradiation without any drug and irradiation under totally hypoxic  
4 conditions were used (**Table 2**). Following  $\gamma$ -ray irradiation, the values  
5 were significantly smaller for Q cells than the total cells ( $P < 0.05$ ),  
6 and in both the total and Q cells, the values were significantly smaller  
7 for RDR than HDR irradiation ( $P < 0.05$ ). In both populations, carbon-ion  
8 beams produced significantly smaller values than  $\gamma$ -rays ( $P < 0.05$ ), and  
9 the values approached to 1.0 as the LET values increased.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

21 To assess the radio-enhancing effect of nicotinamide or  
22 misonidazole under aerobic conditions in both the total and Q cells  
23 compared with aerobic irradiation without any drug, the data for aerobic  
24 irradiation with and without drugs were used (**Table 3**). The enhancing  
25 effect of nicotinamide was more marked in the total cell population,  
26 especially with HDR  $\gamma$ -ray irradiation. The effect was little observed  
27 for RDR  $\gamma$ -ray irradiation and accelerated carbon-ion irradiation  
28 especially with a higher LET value. In contrast, the enhancing effect  
29 of misonidazole was more marked in the Q cells. The enhancing effect  
30 was also attenuated for accelerated carbon-ion irradiation especially  
31 with a higher LET value.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 To investigate the reduction in radiosensitivity caused by a  
47 decrease in radiation dose rate, dose-modifying factors were calculated  
48 using the data for all irradiation conditions given in **Figures 1** through  
49 **5 (Table 4)**. On the whole, the reduction in radiosensitivity was more  
50 marked in Q than the total cells, especially under  $\gamma$ -ray irradiation.  
51 In the total cells, the degree of the reduction of radiosensitivity was  
52 reduced in the following order: aerobic irradiation with nicotinamide  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 > aerobic irradiation without any drug > aerobic irradiation with  
2  
3 misonidazole > irradiation under totally hypoxic conditions. In Q cells,  
4  
5 the degree of the reduction of radiosensitivity was reduced in the  
6  
7 following order: aerobic irradiation with nicotinamide = aerobic  
8  
9 irradiation without any drug > irradiation under totally hypoxic  
10  
11 conditions > aerobic irradiation with misonidazole. This order of the  
12  
13 reduction in radiosensitivity and the difference in the reduction in  
14  
15 radiosensitivity between Q and the total cells became more indistinct  
16  
17 with the use of accelerated carbon-ion beams, especially at a higher  
18  
19 LET value, than with the use of  $\gamma$ -rays.  
20  
21  
22

23 To examine the difference in radiosensitivity between the total  
24  
25 and Q cells, dose-modifying factors, which allow us to compare the dose  
26  
27 of radiation necessary to obtain a normalized MN frequency of 0.2 in  
28  
29 Q cells with that in the total cells, were calculated using the data  
30  
31 in **Figures 2 and 3 (Table 5)**. Overall, the difference in radiosensitivity  
32  
33 was greater under RDR than HDR irradiation, especially with  $\gamma$ -rays. The  
34  
35 difference in radiosensitivity increased in the following order:  
36  
37 irradiation under totally hypoxic conditions < aerobic irradiation with  
38  
39 misonidazole < aerobic irradiation without any drug  $\leq$  aerobic  
40  
41 irradiation with nicotinamide. This order of the increase in the  
42  
43 difference in radiosensitivity and the difference itself in  
44  
45 radiosensitivity became more indistinct with the use of accelerated  
46  
47 carbon-ion beams, especially at a higher LET value, than with the use  
48  
49 of  $\gamma$ -rays.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Discussion

1       Solid tumors, especially human tumors, are thought to contain a  
2  
3       high proportion of Q cells.<sup>6</sup> The presence of Q cell is probably due,  
4  
5       in part, to hypoxia and the depletion of nutrients in the tumor core,  
6  
7       another consequence of poor vascular supply.<sup>6</sup> This might promote the  
8  
9       formation of micronuclei at 0 Gy in Q tumor cells (**Table 1**). Q cells  
10  
11       were shown to have significantly less radiosensitivity than the total  
12  
13       cells here (**Figs. 3 through 5**). This means that more Q cells survive  
14  
15       radiation therapy than P cells. Thus, the control of Q cells has a great  
16  
17       impact on the outcome of radiation therapy. In both the total and Q  
18  
19       cell populations, carbon ion irradiation was less dependent on  
20  
21       oxygenation status with little recovery from radiation-induced DNA  
22  
23       damage, leading to high RBE values compared with  $\gamma$ -ray irradiation.<sup>11</sup>  
24  
25       In terms of the tumor cell-killing effect as a whole, including  
26  
27       intratumor Q cell control, carbon-ion beam radiotherapy can be a  
28  
29       promising treatment for refractory tumors.  
30  
31  
32  
33  
34  
35  
36

37       Q cell population had been shown to include a significantly larger  
38  
39       hypoxic fraction than the total cell population,<sup>12</sup> resulting in a  
40  
41       significantly smaller effect of carbon-ion beams under aerobic  
42  
43       irradiation compared with hypoxic irradiation in Q cells (**Table 2**).  
44  
45       Since tumor radiosensitivity was significantly less dependent on  
46  
47       intratumor oxygenation status and the irradiation dose rate effect when  
48  
49       carbon-ion beams, especially with a higher LET value, were used, a much  
50  
51       smaller effect of aerobic irradiation compared with hypoxic irradiation  
52  
53       was observed here. This was partly because the frequency of closely  
54  
55       spaced DNA lesions forming a cluster of DNA damage produced by high  
56  
57       LET carbon-ion irradiation is much less dependent on oxygenation status  
58  
59  
60  
61  
62  
63  
64  
65

1 at the time of irradiation than that of DNA damage produced by low LET  
2  
3  $\gamma$ -ray irradiation.<sup>13</sup>  
4

5 Tumor hypoxia is a direct consequence of structural abnormalities  
6 of the microvasculature and functional abnormalities of the  
7 microcirculation in solid tumors and results from either limited oxygen  
8 diffusion (chronic hypoxia) or limited perfusion (acute hypoxia,  
9 transient hypoxia, or ischemic hypoxia). Large intercapillary distances  
10 resulting from rapid tumor cell proliferation lead to chronically  
11 hypoxic cells existing at the rim of the oxygen diffusion distance.<sup>14</sup>  
12 Factors such as vessel plugging by blood cells or circulating tumor  
13 cells, the collapse of vessels in regions of high tumor interstitial  
14 pressure, or spontaneous vasomotor activity in normal tissue vessels  
15 incorporated into the tumor which subsequently affects flow in  
16 downstream tumor microvessels cause intermittent blood flow in tumors,  
17 which results in acute hypoxia.<sup>15</sup> Thus, acute hypoxic areas are  
18 distributed throughout the tumor depending on these causative factors  
19 and can occur sporadically in large areas of a solid tumor. Nicotinamide,  
20 a vitamin B<sub>3</sub> analogue, is known to prevent these transient fluctuations  
21 in tumor blood flow that lead to the development of acute hypoxia.<sup>9</sup>  
22 Misonidazole is a typical 2-nitro-imidazole hypoxic cell sensitizer  
23 which is thought to function as an oxygen-mimicking agent in intratumor  
24 hypoxic areas under irradiation.<sup>10</sup> In SCC VII tumors, it had been shown  
25 that the hypoxic fraction of the total cell population is predominantly  
26 made up of acute hypoxic areas and that of the hypoxia rich-Q cell  
27 population is mainly made up of chronic hypoxic areas.<sup>12</sup> Therefore, under  
28 HDR  $\gamma$ -ray irradiation, the enhancement ratio of nicotinamide was higher  
29 in the total cells than in Q cells, and that of misonidazole was higher  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 in the Q cells (**Table 3**). When carbon-ion beams, especially with a higher  
2 LET value, were employed, these differences in the enhancement ratio  
3 were reduced because radiosensitivity was much less dependent on  
4 intratumor oxygenation status.<sup>11</sup> However, under RDR  $\gamma$ -ray irradiation,  
5 acute hypoxic areas appear and disappear throughout a solid tumor during  
6 long periods of irradiation.<sup>15</sup> As a result, RDR irradiation even without  
7 nicotinamide could make it possible to irradiate all acute hypoxic areas  
8 under oxic conditions, leading to no radio-enhancing effect of  
9 nicotinamide. The radio-enhancing effect of misonidazole, which depends  
10 on the size of the hypoxic fraction in solid tumors, however, still  
11 could be observed under RDR as well as HDR irradiation.

12 Enhancement of the irradiation dose rate effect on the normalized  
13 frequency of micronuclei by  $\gamma$ -ray irradiation in the presence of  
14 nicotinamide compared with  $\gamma$ -ray irradiation alone was observed in the  
15 acute hypoxia-rich total cells rather than the chronic hypoxia-rich  
16 Q cells (**Table 4**). Suppression of the dose rate effect by inducing total  
17 hypoxia during irradiation was slightly more clearly observed in  
18 normoxia-rich total cell than hypoxia-rich Q cells. Some recent studies  
19 *in vitro* found that hypoxia-induced translational repression can  
20 explain the decreased homologous recombination (HR) repair of  
21 radiation-induced DNA double-stranded breaks (dsbs),<sup>16</sup> a more important  
22 mechanism for the repair of dsbs in late-S and G2, and that HR plays  
23 a greater role in determining hypoxic radiosensitivity than normoxic  
24 radiosensitivity.<sup>17</sup> Thus, the use of nicotinamide or tumor clamping to  
25 induce total hypoxia influenced repair more in the total cells including  
26 late-S and G2 phase cells than in Q cells. In contrast, the repression  
27 of the dose rate effect by the hypoxic cell radio-sensitizer

1 misonidazole was slightly more clearly observed in the hypoxia-rich  
2  
3 Q cells than normoxia-rich total cells. It had already been shown that  
4  
5 the loading of misonidazole after low LET HDR irradiation to solid tumors  
6  
7 inhibited the recovery from radiation-induced PLD *in vivo*, especially  
8  
9 in Q cells.<sup>18</sup> In this study, it was shown that misonidazole combined  
10  
11 with low LET RDR irradiation could suppress the dose rate effect,  
12  
13 especially in Q cells. According to the previous finding that the  
14  
15 recovery from PLD and the decrease in radiosensitivity through a  
16  
17 reduction in the irradiation dose rate under low LET irradiation are  
18  
19 mainly due to non-homologous end-joining (NHEJ) repair, which is the  
20  
21 predominant DNA dsbs repair process for cells in G<sub>0</sub>, G<sub>1</sub> or early-S phase,<sup>19</sup>  
22  
23 misonidazole itself or protein adducts of reductively-activated  
24  
25 misonidazole in hypoxic areas in irradiated tumors may inhibit NHEJ  
26  
27 more efficiently than HR.<sup>10</sup> Again, when carbon-ion beams, especially  
28  
29 with a higher LET value, were employed, the effects of combined treatment  
30  
31 on the irradiation dose rate effect became indistinct because  
32  
33 radiosensitivity was much less dependent on intratumor oxygenation  
34  
35 status and the irradiation dose rate.<sup>11</sup>

36  
37 Overall, the difference in radiosensitivity between the total and  
38  
39 Q cells was increased by reducing the dose rate, especially for  $\gamma$ -ray  
40  
41 irradiation, because of the greater reduction in radiosensitivity  
42  
43 caused by a decrease in the dose rate in Q cells than in the total cells<sup>9</sup>  
44  
45 (**Table 5**). Nicotinamide enhanced the radiosensitivity of the total cells,  
46  
47 leading to a widening of the difference in radiosensitivity between  
48  
49 the total and Q cell populations compared with aerobic HDR  $\gamma$ -ray  
50  
51 irradiation without any drug. But, for RDR  $\gamma$ -ray irradiation, the effect  
52  
53 of nicotinamide disappeared due to the characteristics of acute hypoxia  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 in solid tumors, resulting in no change in the difference in  
2 **radiosensitivity** between the total and Q cells compared with  $\gamma$ -ray  
3 irradiation only. Meanwhile, under totally hypoxic conditions, the  
4 difference in **radiosensitivity** was smaller than for aerobic  $\gamma$ -ray  
5 irradiation because of the radio-resistance induced by total hypoxia  
6 in both the total and Q cell populations in solid tumors. Misonidazole  
7 enhanced the **radiosensitivity** of the hypoxia-rich Q cells much more  
8 than that of the total cells under both HDR and RDR  $\gamma$ -ray irradiation,  
9 leading to a decrease in the difference in **radiosensitivity** between  
10 the two cells compared with aerobic  $\gamma$ -ray irradiation only. When  
11 carbon-ion beams, especially with a higher LET value, were employed,  
12 the effects of combined treatment on the difference in **radiosensitivity**  
13 between the total and Q cells became indistinct because tumor  
14 **radiosensitivity** was much less dependent on intratumor oxygenation  
15 status and the irradiation dose rate.<sup>11</sup> Anyway, at least in this study,  
16 it was elucidated that manipulating hypoxia during RDR irradiation,  
17 especially with  $\gamma$ -rays, influences tumor **radiosensitivity** as well as  
18 HDR irradiation in both total and Q cell populations. In radiotherapy,  
19 irradiation dose rate also should be taken into account when intratumor  
20 hypoxia is manipulated.

**References**

- 1  
2  
3 1. Ahmed RS, Kim RY, Duan J, Meleth S, De Los Santos JF, Fiveash JB.  
4  
5 IMRT dose escalation for positive para-aortic lymph nodes in patients  
6  
7 with locally advanced cervical cancer while reducing dose to bone  
8  
9 marrow and other organs at risk. *Int J Radiat Oncol Biol Phys*  
10  
11 2005;60:505-512.  
12  
13
- 14 2. Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G, Flentje M.  
15  
16 Stereotactic radiotherapy for primary lung cancer and pulmonary  
17  
18 metastases: a noninvasive treatment approach in medically  
19  
20 inoperable patients. *Int J Radiat Oncol Biol Phys* 2004;60:186-196.  
21  
22
- 23 3. Hall EL, Giaccia AJ. Repair of radiation damage and the dose-rate  
24  
25 effect. In: Hall EJ, Giaccia AJ, editors. *Radiobiology for the*  
26  
27 *Radiologist*, 6th ed. Philadelphia, Lippincott Williams & Wilkins;  
28  
29 2006 p 60-84.  
30  
31
- 32 4. Hall EL, Giaccia AJ. Linear energy transfer and relative biological  
33  
34 effectiveness. In: Hall EJ, Giaccia AJ, editors. *Radiobiology for*  
35  
36 *the Radiologist*, 6th ed. Philadelphia, Lippincott Williams &  
37  
38 Wilkins; 2006 p 106-116.  
39  
40
- 41 5. Hall EL, Giaccia AJ. Oxygen effect and reoxygenation. In: Hall EJ,  
42  
43 Giaccia AJ, editors. *Radiobiology for the Radiologist*, 6th ed.  
44  
45 Philadelphia, Lippincott Williams & Wilkins; 2006 p 85-105.  
46  
47
- 48 6. Vaupel P. Tumor microenvironmental physiology and its implications  
49  
50 for radiation oncology. *Semin Radiat Oncol* 2004;14:197-275.  
51  
52
- 53 7. Masunaga S, Ono K. Significance of the response of quiescent cell  
54  
55 populations within solid tumors in cancer therapy. *J Radiat Res*  
56  
57 2002;43:11-25.  
58  
59
- 60 8. Torikoshi M, Minohara S, Kanematsu N, Komori M, Kanazawa M, Noda  
61  
62  
63  
64  
65

1 K, et al. Irradiation system for HIMAC. J Radiat Res  
 2  
 3 2007;48 (Suppl) :A15-A25.  
 4

5 9. Chaplin DJ, Horsman MR, Trotter MJ. Effect of nicotinamide on the  
 6  
 7 microregional heterogeneity of oxygen delivery within a murine tumor.  
 8  
 9 J Natl Cancer Inst 1990;82:672-676.  
 10

11  
 12 10. Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin  
 13  
 14 Oncol 2007;19:397-417.  
 15

16  
 17 11. Masunaga S, Ando K, Uzawa A, Hirayama R, Furusawa Y, Sakurai Y, et  
 18  
 19 al. Radiobiologic significance of the response of intratumor  
 20  
 21 quiescent cells *in vivo* to accelerated carbon ion beams compared  
 22  
 23 with  $\gamma$ -rays and reactor neutron beams. Int J Radiat Oncol Biol Phys  
 24  
 25 2008;70:221-228.  
 26

27  
 28 12. Masunaga S, Ono K, Suzuki M, Nishimura Y, Hiraoka M, Kinashi Y, et  
 29  
 30 al. Alteration of the hypoxic fraction of quiescent cell populations  
 31  
 32 by hyperthermia at mild temperatures. Int J Hyperthermia  
 33  
 34 1997;13:401-411.  
 35

36  
 37 13. Hada M, Georgakilas AG. Formation of clustered DNA damage after  
 38  
 39 high-LET irradiation: a Review. J Radiat Res 2008;49:203-210.  
 40

41  
 42 14. Thomlinson RH, Gray LH. The histological structure of some human  
 43  
 44 lung cancers and the possible implications for radiotherapy. Br J  
 45  
 46 Cancer 1955;9:539-549.  
 47

48  
 49 15. Brown JM. Evidence of acutely hypoxic cells in mouse tumours, and  
 50  
 51 a possible mechanism of reoxygenation. Br J Radiol 1979;52:650-656.  
 52

53  
 54 16. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, et  
 55  
 56 al. Chronic hypoxia decreases synthesis of homologous recombination  
 57  
 58 proteins to offset chemoresistance and radioresistance. Cancer Res  
 59  
 60 2008;68:605-614.  
 61  
 62  
 63  
 64  
 65

- 1 17. Sprong D, Janssen HL, Vens C, Begg AC. Resistance of hypoxic cells  
2 to ionizing radiation is influenced by homologous recombination  
3 status. Int J Radiat Oncol Biol Phys 2006;64:562-572.  
4  
5  
6  
7 18. Masunaga S, Ono K, Abe M. Potentially lethal damage repair by  
8 quiescent cells in murine solid tumors. Int J Radiat Oncol Biol Phys  
9  
10  
11  
12 1992;22:973-978.  
13  
14 19. Masunaga S, Nagata K, Suzuki M, Kashino G, Kinashi Y, Ono K.  
15  
16 Inhibition of repair from radiation-induced damage by mild  
17  
18 temperature hyperthermia, referring to the effect on quiescent cell  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Captions for Illustrations**

1  
2  
3 **Fig. 1.** Cell survival curves for the total tumor cell population as  
4 a function of radiation dose after  $\gamma$ -ray irradiation. Open and  
5 solid symbols represent the surviving fractions after high  
6 dose-rate and reduced dose-rate  $\gamma$ -ray irradiation,  
7 respectively. Circles, reversed triangles, triangles, and  
8 squares represent the surviving fractions after aerobic  
9 irradiation without any drug, irradiation under totally  
10 hypoxic conditions, aerobic irradiation after nicotinamide  
11 (NA) loading, and aerobic irradiation after misonidazole  
12 (MISO) loading, respectively. Bars represent standard errors.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25  
26 **Fig. 2.** Cell survival curves for the total tumor cell population as  
27 a function of radiation dose after accelerated carbon-ion beam  
28 irradiation with an LET of 18 and 50 keV/ $\mu$ m are shown in the  
29 left and right panels, respectively. Open and solid symbols  
30 represent the surviving fractions after high dose-rate and  
31 reduced dose-rate accelerated carbon-ion beam irradiation,  
32 respectively. Circles, reversed triangles, triangles, and  
33 squares represent the surviving fractions after aerobic  
34 irradiation without any drug, irradiation under totally  
35 hypoxic conditions, aerobic irradiation after nicotinamide  
36 (NA) loading, and aerobic irradiation after misonidazole  
37 (MISO) loading, respectively. Bars represent standard errors.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 **Fig. 3.** Dose response curves of the normalized micronucleus frequency  
54 for the total and quiescent tumor cell populations as a  
55 function of radiation dose after  $\gamma$ -ray irradiation are shown  
56 in the left and right panels, respectively. Open and solid  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 symbols represent the normalized micronucleus frequencies  
2 after high dose-rate and reduced dose-rate  $\gamma$ -ray irradiation,  
3 respectively. Circles, reversed triangles, triangles, and  
4 squares represent the normalized micronucleus frequencies  
5 after aerobic irradiation without any drug, irradiation under  
6 totally hypoxic conditions, aerobic irradiation after  
7 nicotinamide (NA) loading, and aerobic irradiation after  
8 misonidazole (MISO) loading, respectively. Bars represent  
9 standard errors.

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21 **Fig. 4.** Dose response curves of the normalized micronucleus frequency  
22 for the total and quiescent tumor cell populations as a  
23 function of radiation dose after accelerated carbon-ion beam  
24 irradiation with an LET of 18 keV/ $\mu$ m are shown in the left and  
25 right panels, respectively. Open and solid symbols represent  
26 the normalized micronucleus frequencies after high dose-rate  
27 and reduced dose-rate accelerated carbon-ion beam irradiation,  
28 respectively. Circles, reversed triangles, triangles, and  
29 squares represent the normalized micronucleus frequencies  
30 after aerobic irradiation without any drug, irradiation under  
31 totally hypoxic conditions, aerobic irradiation after  
32 nicotinamide (NA) loading, and aerobic irradiation after  
33 misonidazole (MISO) loading, respectively. Bars represent  
34 standard errors.

35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53 **Fig. 5.** Dose response curves of the normalized micronucleus frequency  
54 for the total and quiescent tumor cell populations as a  
55 function of radiation dose after accelerated carbon-ion beam  
56 irradiation with an LET of 50 keV/ $\mu$ m are shown in the left and  
57 right panels, respectively. Open and solid symbols represent  
58 the normalized micronucleus frequencies after high dose-rate  
59 and reduced dose-rate accelerated carbon-ion beam irradiation,  
60 respectively. Circles, reversed triangles, triangles, and  
61 squares represent the normalized micronucleus frequencies  
62 after aerobic irradiation without any drug, irradiation under  
63 totally hypoxic conditions, aerobic irradiation after  
64 nicotinamide (NA) loading, and aerobic irradiation after  
65 misonidazole (MISO) loading, respectively. Bars represent  
standard errors.



1 right panels, respectively. Open and solid symbols represent  
2  
3 the normalized micronucleus frequencies after high dose-rate  
4  
5 and reduced dose-rate accelerated carbon-ion beam irradiation,  
6  
7 respectively. Circles, reversed triangles, triangles, and  
8  
9 squares represent the normalized micronucleus frequencies  
10  
11 after aerobic irradiation without any drug, irradiation under  
12  
13 totally hypoxic conditions, aerobic irradiation after  
14  
15 nicotinamide (NA) loading, and aerobic irradiation after  
16  
17 misonidazole (MISO) loading, respectively. Bars represent  
18  
19 standard errors.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Table 1.

## Plating efficiency and micronucleus frequency at 0 Gy

	Total tumor cells	Quiescent cells
<b>&lt;Plating efficiency (%)&gt;</b>		
Absolutely control	53.7 ± 8.5 <sup>a</sup>	----
Totally hypoxic	50.1 ± 7.0	----
+ Nicotinamide	46.8 ± 0.6	----
+ Misonidazole	31.2 ± 7.7	
<b>&lt;Micronucleus frequency&gt;</b>		
Absolutely control	0.043 ± 0.005	0.063 ± 0.009
Totally hypoxic	0.058 ± 0.006	0.073 ± 0.010
+ Nicotinamide	0.073 ± 0.009	0.119 ± 0.014
+ Misonidazole	0.093 ± 0.011	0.152 ± 0.018

<sup>a</sup>; Mean ± standard deviation

Table 2.

**Irradiation under aerobic conditions  
compared with irradiation under hypoxic conditions<sup>a</sup>**

$\gamma$ -Rays	Carbon-ion beams (18 keV/ $\mu$ m)	Carbon-ion beams (50 keV/ $\mu$ m)
<b>&lt;Surviving fraction = 0.3&gt;</b>		
<b><u>Total cells</u></b>		
High dose-rate irradiation		
2.1 (2.0-2.2) <sup>b</sup>	1.4 (1.3-1.5)	1.15 (1.1-1.2)
Reduced dose-rate irradiation		
1.8 (1.7-2.0)	1.25 (1.15-1.35)	1.1 (1.05-1.15)
<b>&lt;Normalized micronucleus frequency = 0.2&gt;</b>		
<b><u>Total cells</u></b>		
High dose-rate irradiation		
1.9 (1.8-2.0)	1.35 (1.25-1.45)	1.2 (1.1-1.3)
Reduced dose-rate irradiation		
1.7 (1.6-1.8)	1.25 (1.15-1.35)	1.15 (1.1-1.2)
<b><u>Quiescent cells</u></b>		
High dose-rate irradiation		
1.5 (1.4-1.6)	1.25 (1.15-1.35)	1.15 (1.1-1.2)
Reduced dose-rate irradiation		
1.3 (1.2-1.4)	1.1 (1.05-1.15)	1.05 (1.0-1.1)

<sup>a</sup>; The ratio of the dose of radiation necessary to obtain each end-point under hypoxic conditions to that needed to obtain each end-point under aerobic conditions.

<sup>b</sup>; Values in parentheses are 95% confidence limits, determined using standard errors. If the ranges of 95 % confidence limits showed no overlap between any two values, the difference between the two values was considered significant ( $p < 0.05$ ).

Table 3.

Enhancement ratios<sup>a</sup> due to combination  
with nicotinamide or misonidazole

	High dose rate irradiation	Reduced dose rate irradiation
<b>&lt;Surviving fraction = 0.3&gt;</b>		
<b><u>Total cells</u></b>		
<b><math>\gamma</math>-Rays</b>		
+ Nicotinamide	1.3 (1.2-1.4) <sup>b</sup>	1.05 (1.0-1.1)
+ Misonidazole	1.8 (1.6-2.0)	1.85 (1.7-2.0)
<b>Carbon-ion beams (18 keV/<math>\mu</math>m)</b>		
+ Nicotinamide	1.15 (1.1-1.2)	1.05 (1.0-1.1)
+ Misonidazole	1.3 (1.2-1.4)	1.35 (1.3-1.4)
<b>Carbon-ion beams (50 keV/<math>\mu</math>m)</b>		
+ Nicotinamide	1.05 (1.0-1.1)	1.05 (1.0-1.1)
+ Misonidazole	1.1 (1.05-1.15)	1.15 (1.1-1.2)
<b>&lt;Normalized micronucleus frequency = 0.2&gt;</b>		
<b><u>Total cells</u></b>		
<b><math>\gamma</math>-Rays</b>		
+ Nicotinamide	1.2 (1.1-1.3)	1.05 (1.0-1.1)
+ Misonidazole	1.3 (1.2-1.4)	1.35 (1.25-1.45)
<b>Carbon-ion beams (18 keV/<math>\mu</math>m)</b>		
+ Nicotinamide	1.15 (1.1-1.2)	1.05 (1.0-1.1)
+ Misonidazole	1.2 (1.1-1.3)	1.25 (1.15-1.35)
<b>Carbon-ion beams (50 keV/<math>\mu</math>m)</b>		
+ Nicotinamide	1.05 (1.0-1.1)	1.05 (1.0-1.1)
+ Misonidazole	1.05 (1.0-1.1)	1.05 (1.0-1.1)
<b><u>Quiescent cells</u></b>		
<b><math>\gamma</math>-Rays</b>		
+ Nicotinamide	1.1 (1.05-1.15)	1.05 (1.0-1.1)
+ Misonidazole	1.45 (1.35-1.55)	1.5 (1.4-1.6)
<b>Carbon-ion beams (18 keV/<math>\mu</math>m)</b>		
+ Nicotinamide	1.05 (1.0-1.1)	1.0 (0.95-1.05)
+ Misonidazole	1.25 (1.15-1.35)	1.3 (1.2-1.4)
<b>Carbon-ion beams (50 keV/<math>\mu</math>m)</b>		
+ Nicotinamide	1.05 (1.0-1.1)	1.0 (0.95-1.05)
+ Misonidazole	1.1 (1.05-1.15)	1.1 (1.05-1.15)

<sup>a</sup>; The ratio of the dose of radiation necessary to obtain each end-point without the drug to that needed to obtain each end-point with the drug.

<sup>b</sup>; As in Table 2.

Table 4.

Dose-modifying factors due to the reduction in **radiosensitivity** caused by a decrease in radiation dose rate<sup>a</sup>

$\gamma$ -Rays	Carbon-ion beams (18 keV/ $\mu$ m)	Carbon-ion beams (50 keV/ $\mu$ m)
<b>&lt;Surviving fraction = 0.3&gt;</b>		
<b><u>Total cells</u></b>		
Radiation only		
1.3 (1.2-1.4) <sup>b</sup>	1.2 (1.1-1.3)	1.15 (1.1-1.2)
Totally hypoxic		
1.2 (1.1-1.3)	1.15 (1.05-1.25)	1.1 (1.05-1.15)
+ Nicotinamide		
1.55 (1.4-1.7)	1.35 (1.25-1.45)	1.2 (1.15-1.25)
+ Misonidazole		
1.25 (1.15-1.35)	1.2 (1.1-1.3)	1.15 (1.1-1.2)
<b>&lt;Normalized micronucleus frequency = 0.2&gt;</b>		
<b><u>Total cells</u></b>		
Radiation only		
1.25 (1.15-1.35)	1.2 (1.1-1.3)	1.1 (1.05-1.15)
Totally hypoxic		
1.15 (1.1-1.2)	1.1 (1.05-1.15)	1.05 (1.0-1.1)
+ Nicotinamide		
1.4 (1.25-1.55)	1.3 (1.2-1.4)	1.2 (1.1-1.3)
+ Misonidazole		
1.2 (1.1-1.3)	1.15 (1.05-1.25)	1.1 (1.05-1.15)
<b><u>Quiescent cells</u></b>		
Radiation only		
1.4 (1.3-1.5)	1.3 (1.2-1.4)	1.25 (1.15-1.35)
Totally hypoxic		
1.25 (1.15-1.35)	1.15 (1.1-1.2)	1.1 (1.05-1.15)
+ Nicotinamide		
1.4 (1.3-1.5)	1.3 (1.2-1.4)	1.25 (1.15-1.35)
+ Misonidazole		
1.15 (1.1-1.2)	1.1 (1.05-1.15)	1.1 (1.05-1.15)

<sup>a</sup>; The ratio of the dose of radiation necessary to obtain each end-point with reduced dose-rate irradiation to that needed to obtain each end-point with high dose-rate irradiation.

<sup>b</sup>; As in Table 2.

Table 5.

**Dose-modifying factors for quiescent cells  
relative to total tumor cells<sup>a</sup>**

$\gamma$ -Rays	Carbon-ion beams (18 keV/ $\mu$ m)	Carbon-ion beams (50 keV/ $\mu$ m)
<b>&lt;Normalized micronucleus frequency = 0.2&gt;</b>		
<b><u>High dose rate irradiation</u></b>		
<b>Radiation only</b>		
1.65 (1.5-1.8) <sup>b</sup>	1.45 (1.35-1.55)	1.35 (1.25-1.45)
<b>Totally hypoxic</b>		
1.4 (1.15-1.55)	1.3 (1.2-1.4)	1.25 (1.15-1.35)
<b>+ Nicotinamide</b>		
1.75 (1.6-1.9)	1.5 (1.4-1.6)	1.4 (1.3-1.5)
<b>+ Misonidazole</b>		
1.5 (1.35-1.65)	1.35 (1.25-1.45)	1.3 (1.2-1.4)
<b><u>Reduced dose rate irradiation</u></b>		
<b>Radiation only</b>		
1.85 (1.7-2.0)	1.6 (1.5-1.7)	1.5 (1.4-1.6)
<b>Totally hypoxic</b>		
1.45 (1.35-1.55)	1.35 (1.25-1.45)	1.3 (1.2-1.4)
<b>+ Nicotinamide</b>		
1.85 (1.7-2.0)	1.6 (1.5-1.7)	1.5 (1.4-1.7)
<b>+ Misonidazole</b>		
1.55 (1.45-1.65)	1.4 (1.3-1.5)	1.35 (1.25-1.45)

<sup>a</sup>; The ratio of the dose of radiation necessary to obtain each normalized micronucleus frequency in quiescent cell population to that needed to obtain each normalized micronucleus frequency in total tumor cell population.

<sup>b</sup>; As in Table 2.

Figure 1  
[Click here to download high resolution image](#)




Figure 2  
[Click here to download high resolution image](#)






Figure 3  
[Click here to download high resolution image](#)




Figure 4  
[Click here to download high resolution image](#)





Figure 5  
[Click here to download high resolution image](#)



**Acknowledgments**

This study was supported, in part, by a Grant-in-aid for Scientific Research (C) (20591493) from the Japan Society for the Promotion of Science.